Posted by Michael Wonder on 27 Aug 2019
European Commission approves Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
27 August 2019 - Median progression-free survival and overall response rate doubled among patients receiving EPd compared to pomalidomide and low-dose dexamethasone alone.
Bristol-Myers Squibb Company today announced that the European Commission has approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.
This approval is based on data from the ELOQUENT-3 trial in which EPd doubled both median progression-free survival and overall response rate among patients with relapsed and refractory multiple myeloma versus pomalidomide and low-dose dexamethasone alone.
